Report of Foreign Issuer (6-k)
December 21 2018 - 8:12AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of:
December 2018
Commission file number:
001- 38041
THERAPIX BIOSCIENCES LTD.
(Translation of registrant’s name
into English)
4 Ariel Sharon Street
HaShahar Tower, 16th Floor
Givatayim 5320047, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____
INFORMATION CONTAINED IN THIS FORM 6-K
REPORT
On December 21, 2018, Therapix Biosciences Ltd. (the “
Company
”)
issued a press release announcing that the Company has delivered a notice of termination to FSD Pharma Inc. (“
FSD
”)
under the previously announced binding letter of intent dated October 22, 2018 between the Company and FSD. The press release is
attached as Exhibit 99.1 to this report.
The information contained in this Report on Form 6-K is hereby
incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-225745) and Registration Statement
on Form S-8 (File No. 333-225773).
Forward Looking Statements:
Matters discussed in this Report on Form 6-K contain forward-looking
statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995
and other Federal securities laws. Because such statements deal with future events and are based on the Company’s current
expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of the Company
could differ materially from those described in or implied by the statements in this report. The forward-looking statements contained
or implied in this report are subject to other risks and uncertainties, including those discussed under the heading “Risk
Factors” in the Company’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (“
SEC
”)
on April 30, 2018 and in subsequent filings with the SEC. Except as otherwise required by law, the Company disclaims any intention
or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a
result of new information, future events or circumstances or otherwise.
Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
Therapix Biosciences Ltd.
|
|
|
|
Date: December 21, 2018
|
By
|
/s/ Ascher Shmulewitz
|
|
Name:
|
Ascher Shmulewitz, M.D, Ph.D.
|
|
Title:
|
Chief Executive Officer
|
Therapix Biosciences (NASDAQ:TRPX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Therapix Biosciences (NASDAQ:TRPX)
Historical Stock Chart
From Apr 2023 to Apr 2024